66 results about "In vitro test" patented technology

The invention discloses a method and a system for testing corrosion fatigue of a bone implantation device under a pathological condition, and relates to the technical field of orthopedic medical device evaluation, and the method comprises the following steps: constructing a dynamic load spectrum database covering physiological and pathological states; in-vitro reproduction of a dynamic mechanical environment borne by the bone implantation instrument in physiological and pathological states is completed through a multi-axis servo system; and acquiring service state data of the bone implantation instrument, and analyzing the service state data of the bone implantation instrument to obtain coupling experiment data. According to the invention, the defects of single load mode and environment simulation distortion in the traditional test method are overcome, high-fidelity simulation and comprehensive monitoring of the corrosion fatigue behavior of the bone implantation device under the pathological condition are realized, the consistency of the in-vitro test result and the in-vivo actual service performance is improved, and the application prospect is wide. And a scientific and unified evaluation basis is provided for material screening, structure optimization and service life evaluation of different types of bone implantation instruments.

Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

Relacorilant is useful in the treatment of hypercortisolism and cancer. Many drugs useful in treating hypercortisolism or cancer are metabolized by CYP2C9 enzymes. The effects of concomitant administration of relacorilant and a CYP2C9 substrate are disclosed herein.Relacorilant potently inhibited CYP2C9 in an in vitro test, indicating that co-administration of relacorilant and a CYP2C9 substrate would be expected to increase the CYP2C9 substrate plasma exposure more than five-fold in vivo. Significant reductions in CYP2C9 substrate doses would be expected to be required when administered with relacorilant.Surprisingly, no such increase in plasma exposure was seen in human studies. Applicant discloses that relacorilant may be safely co-administered with unmodified doses of a CYP2C9 substrate such as, e.g., tolbutamide, glimepiride, and glipizide. Relacorilant and unmodified doses of CYP2C9 substrate such as tolbutamide, glimepiride, and glipizide may be co-administered to treat hypercortisolism, or may be co-administered to a cancer patient.

The present invention provides a sunscreen composition comprising: (i) TiO2, (ii) ZnO, (iii) triacontanyl PVP, and (iv) VP / hexadecene copolymer, wherein the composition is an oil-in-water emulsion substantially free of low molecular weight, organic UV absorbers, the ratio of (iii):(iv) is less than one, and the composition provides an in vitro SPF as measured by the IN VITRO SPF TEST METHOD of at least 25. The composition is surprisingly low viscosity and provides a high SPF.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in macrophage polarization and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect multiple cell factors, the sample dosage is only 25 microliters, the kit is suitable for in-vitro tests of mouse mononuclear macrophage leukemia cell lines RAW264.7, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

The invention provides periorbital secretion inhibition gel containing natural plant polyphenols and a preparation method thereof, and relates to the field of pet eye care, the gel is chelated with iron ions through EGCG to block a porphyrin oxidation pathway, cooperates with zinc ions to inhibit bacterial growth and plays a role in multiple mechanisms of targeted removal of bacterial biofilms through antibacterial peptide LL-37; in-vitro tests prove that the functional components in the gel have a remarkable synergistic effect, proliferation of staphylococcus aureus can be effectively inhibited, deposition of porphyrin is remarkably inhibited, and formation of tear stains is relieved; animal experiment results show that the gel has a remarkable tear stain removal effect and good periorbital safety, after two weeks of treatment, the periorbital tear stain area is reduced by 75.97% compared with that of a bear dog, the eye McDonald-Shiadduck stimulation score is also remarkably reduced, corneal fluorescein staining detection results of all tested animals are negative, and the gel has a good clinical application prospect. A mild and effective new thought is provided for inhibiting the periocular secretions of the pets.

An ex vivo test system 10 is constituted of a fluid circuit that circulates a prescribed circulation liquid by simulating the blood circulation state of a human body, and comprises a circulation liquid maintenance unit 17 that maintains, in the same manner as the blood environment in vivo, chemical factors in the circulation liquid, which affect the performance evaluation of a test object S. The circulation liquid maintenance unit 17 comprises: a replenishing liquid unit 23 that maintains the chloride ion concentration and protein concentration of the circulation liquid at desired values by injecting a replenishing liquid composed of an electrolyte-free isotonic solution into the fluid circuit; and a carbon dioxide supply unit 24 that maintains the pH of the circulation liquid at a desired value by supplying carbon dioxide into the fluid circuit, the state of the circulation liquid being maintained while compensating for the effect of moisture loss during circulation of the circulation liquid.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

This invention relates to the field of medical device technology, and in particular to an in vitro testing phantom, in vitro testing system, and method for assessing the application accuracy of a robot system. The in vitro testing phantom includes a first phantom with a first positioning point for inserting a test specimen; and a second phantom adapted to the first phantom and having a second positioning point. After the first and second phantoms are installed, the relative positions of the first and second positioning points are determined, and the projections of the first and second positioning points relative to the same plane at least partially overlap. Its advantage lies in that the first and second positioning points can cooperate to form a channel through which the test specimen can pass, thereby testing the application accuracy of the robot system. Only by changing the shape and size of the second positioning point can the accuracy requirements for the test specimen be changed, thus expanding the application range of the testing phantom.

The present invention provides a phenylpropionic acid derivative, a preparation method, an antioxidant, and applications thereof, belonging to the fields of medicine, health, and the food industry. The phenylpropionic acid derivative is ethane-1,2-diyl bis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propanoate). The present invention provides a new use for a phenylpropionic acid derivative. In vitro tests have confirmed that the phenylpropionic acid derivative provided by the present invention has good in vitro antioxidant activity and can be used as an active ingredient in an antioxidant, thus having a wide range of applications.

The present invention relates to a defect detection device for an in vitro test strip, which comprises a detector body. A light mirror is fixedly installed on one side of the detector body. Air-dissipating blades placed on a housing are provided on both sides outside the light mirror. A lifting device connected to a top plate is installed on the top of the detector body through a rotating device. Positioning holes adapted to the outer wall of the top plate are formed around the outer wall of the top plate. The rotating device comprises a rotating disk located at the top of the housing. The top of the rotating disk is driven by a first motor, and a U-shaped plate is fixedly clamped to the outer wall of the first motor through a mounting groove. A pin shaft is fixedly connected through the U-shaped plate. A second motor adapted to the outer wall of the pin shaft and fixed on an external cross beam is connected to the outer wall of the pin shaft. The U-shaped plate and the lifting device are fixedly welded through a guard plate. The lifting device comprises a third motor, and a lead screw is fixedly installed on the third motor. Beneficial effects: The present invention is reasonably designed, has various adjustment methods, high recognition accuracy, can improve the accuracy of data detection, and has strong application performance.

The present invention discloses a strain of Bacillus subtilis and its application, belonging to the technical field of probiotic R & D. In the present invention, a strain of Bacillus subtilis is identified by traditional isolation and culture, morphological, physiological and biochemical, and molecular biological methods, and its probiotic properties are evaluated by in vitro and in vivo tests. The results of in vitro tests show that the strain can tolerate acid (the lowest pH is 2), tolerate salt (the highest NaCl concentration is 10%), is non-hemolytic, inhibits pathogenic bacteria, and is sensitive to most antibiotics; the results of in vivo tests show that adding the strain can improve the production performance of animals, promote the absorption of nutrients by the small intestine, and increase the diversity of dominant intestinal flora. The present invention can not only expand the research on Bacillus subtilis, but also provide a reference basis for the future development of probiotic preparations for antagonizing pathogenic bacteria and regulating the intestinal microecological balance, etc.

The present invention relates to an antibacterial mefenamic acid silver complex, and its preparation method and application. An antibacterial mefenamic acid silver complex, whose pharmaceutically acceptable compound structure is as follows:. The preparation method of the mefenamic acid silver complex comprises the following steps: first, reacting the ligand mefenamic acid with sodium ethoxide to generate mefenamic acid sodium salt; then, adding the obtained mefenamic acid sodium salt dropwise to a silver nitrate solution; and slowly volatilizing for 3 days to obtain colorless crystals, namely the mefenamic acid silver complex. The mefenamic acid silver complex has an excellent inhibitory effect on common bacteria, and is superior to silver nitrate or mefenamic acid in in vitro tests, and has the potential to replace or supplement existing antibacterial agents on the market. The antibacterial mefenamic acid silver complex or its salt is used as an active component in the preparation of antibacterial agents.

Systems, devices, kits, and methods are provided herein in the form of example embodiments that relate to calibration of medical devices. The medical devices can be sensors adapted to sense a biochemical attribute. The embodiments can be used to determine calibration information specific to an individual medical device. The embodiments can determine the calibration information by reference to one or more parameters obtained during manufacturing of the medical device. The embodiments can also determine the calibration information by reference to in vitro testing of the medical devices. The embodiments also apply to systems incorporating those medical devices in their use in the field. Also described are embodiments of modifications to surfaces of sensor substrates, such as through applied radiation and / or the creation of a well, to aid in the placement and / or sizing of a sensor element on the substrate.

The invention discloses an application of mulberone H in preparation of a medicine for treating or preventing PEDV (Porcine Epidemic Diarrhea Virus) infection. In-vitro test results prove that the mulberone H significantly inhibits the enzyme digestion activity of PEDV 3C-like protease, and further verifies that the mulberone H inhibits PEDV infected cells, so that the mulberone H can be used for preparing the medicine for preventing and treating PEDV. Besides, mulberone H, as a natural substance separated from mulberries, can be used as a feed additive for a long time so as to achieve the purpose of preventing epidemic diseases, does not cause generation of drug-resistant strains after long-term use, and does not have other toxic or side effects. The defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome.

This invention discloses a semi-sandwich structured ruthenium triphenylphosphine dithiocarboxylic acid complex with a simple preparation process and its applications. The complex has the structure shown in Figure (I), with the central ruthenium and... η 5 - Coordination with cyclopentadiene, triphenylphosphine, and dithiocarboxylic acid derivatives, wherein the dithiocarboxylic acid ligands are selected from ethyl xanthic acid, isopropyl xanthic acid, ... N,N Diethyldithiocarbamic acid, morpholine dithiocarbamic acid, and carbazole dithiocarbamic acid. This invention employs a simple one-step method of room temperature preparation and recrystallization purification using a ruthenium precursor and dithiocarbamic acid ligand. This method offers advantages such as readily available raw materials, mild reaction conditions, simple post-processing, and high yield. In vitro tests show that the complexes exhibit excellent anti-proliferative activity against non-small cell lung cancer A549 cells, significantly superior to cisplatin. The complexes demonstrate activity by reducing mitochondrial membrane potential, inducing intracellular reactive oxygen species accumulation, and arresting the cell cycle (G1 phase), leading to late apoptosis in A549 cells.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

A new, original and ornamental design for a recyclable in vitro test system, comprising a diagnostic unit and a diagnostic reagent which is convertible into a optically perceptible diagnostic product by bringing it into contact with a sample material, wherein a housing surrounds the diagnostic unit at least in sections; the accompanying drawings refer for the above specified recyclable in vitro test system; design 1: view 1 shows a top view of the in vitro test system; view 2 shows a bottom view of the in vitro test system; view 3 shows a side view of the in vitro test system; view 4 shows front view of the in vitro test system; view 5 shows a perspective view of the in vitro test system from an oblique front view; design 2: view 1 shows a top view of the in vitro test system; view 2 shows a bottom view of the in vitro test system; view 3 shows a side view of the in vitro test system; view 4 shows front view of the in vitro test system; view 5 shows a perspective view of the in vitro test system from an oblique front view.

The present application relates to the technical field of veterinary medicine preparation, and particularly relates to a water-soluble medicine gastro-resistant and enteric-coated granule, a preparation method and application thereof, the coated granule comprising: an inner core of at least one water-soluble medicine active ingredient, a coating layer coated outside the inner core; and the coating layer is formed by a composite coating material of hydrogenated palm oil and lipophilic hydrophobic nano active light calcium carbonate. The present application has the advantages that the nano calcium carbonate is used to form pores in the true stomach by acid reaction and to produce gas by saponification with fatty acids in the intestinal tract, so that the water-soluble medicine is efficiently protected in the rumen and rapidly and completely released in the intestinal tract. In vitro tests show that the effective release rate can reach more than 79%, which is significantly better than the traditional coating, and has a broad clinical application prospect.

The present disclosure relates to compositions of biocompounds derived from cacao, mainly aromatic compounds such as flavanols and methylxanthines in the form of suspended particles, and to methods for producing the compositions from cacao beans, in particular unfermented cacao beans. The disclosed compositions have high concentrations of epicatechin, procyanidin B2 and theobromine and demonstrate high bioavailability in in vitro tests. These results suggest that the compositions developed are potentially useful for producing functional foods.

This invention relates to the field of computational toxicology, and in particular to a precise method for comparing the consistency of animal and non-animal toxicity evaluation results. This method acquires in vivo baseline data from animals and in vitro test data from non-animals. It employs a dynamic time warping algorithm and radial basis function kernel function to construct correction coefficients and perform equivalent mapping to generate a converted sequence. Based on a binary classification mapping of toxicity thresholds, a confusion matrix is ​​constructed to calculate sensitivity, specificity, and predicted values. Each indicator is treated as an independent source of evidence, and the Mahalanobis distance is calculated using the covariance matrix to generate a basic probability allocation function. The D-S evidence theory combination rule is applied for fusion, and a secondary factor allocation is introduced when there is conflict. Finally, the result is compared with a preset threshold to determine the feasibility of substitution. This invention adaptively eliminates the nonlinear misalignment difference between in vivo and in vitro dose responses, providing an objective quantitative judgment standard for toxicological substitution verification.

The invention provides an isophorone dye derivative LYC-CF3 as well as a synthesis method and application thereof. The specific name of the isophorone dye derivative is (E)-4-(2-(3-(dicyanomethylene)-5, 5-dimethylcyclohex-1-ene-1-yl) vinyl)-2-(trifluoromethyl) phenyl trifluoromethanesulfonate, and the structural formula of the isophorone dye derivative is shown in the description. The invention also provides a synthesis method of the derivative LYC-CF3, and a fluorescence imaging experiment of the derivative LYC-CF3 on O2 <-> in PC-12 cells. Through verification of a fluorescence spectrum and a laser confocal microscope, the derivative LYC-CF3 has quick response to O2 <-> in an in-vitro test and cells and relatively remarkable fluorescence imaging capability. Therefore, LYC-CF3 can be used as a fluorescent probe for in-vitro detection of O2 <-> and detection of O2 <-> in cells.

The present disclosure provides a system, device, control method and storage medium for simulating physical characteristics of blood vessels. The method for simulating physical characteristics of blood vessels comprises determining blood vessel types of a lesion to be studied, collecting clinical medical data of the lesion blood vessels, performing isolated modeling on each blood vessel branch, setting initial reference values of the model, connecting the blood vessel model and the device for simulating physical characteristics of blood vessels to an in-vitro test device, operating the in-vitro test device based on the initial reference values, and calculating blood vessel resistance, compliance and test temperature in the blood vessel model in real time according to sensor collected data, and calculating differences between target values and corresponding measured values. The in-vitro test device is adjusted through a simulated neural feedback mechanism and a direct coordination mechanism of each blood vessel branch until the differences between the target values and the corresponding measured values meet predetermined conditions.

In recent years, in an attempt to identify new therapies and more accurate biomarkers for the early diagnosis and treatment of liver diseases, to date, no biomarkers exist that allow for a definitive determination of the prognosis of patients with hepatic fibrosis. The present invention relates to a panel of biomarkers for in vitro testing in the diagnosis of liver disease, particularly for clinical diagnosis, with an emphasis on in vitro tests for diagnosing diseases associated with fibrosis, such as the detection of hepatic fibrosis processes using non-invasive methods in patients, as well as in individuals without known liver disease.

The invention discloses an application of phellinus linteus in preparation of a medicine for treating or preventing PEDV (Porcine Epidemic Diarrhea Virus) infection. In-vitro test results prove that the phellinus linteus can significantly inhibit the enzyme digestion activity of PEDV 3C-like protease, and further verify that the phellinus linteus can inhibit PEDV infection cells, so that the phellinus linteus can be used for preparing the medicine for preventing and treating PEDV. Besides, the phellinus linteus ketone is an active component extracted from moraceae plants, belongs to a natural isopentene flavonoid compound, can be used as a feed additive for a long time so as to achieve the purpose of preventing epidemic diseases, does not cause generation of drug-resistant strains after being used for a long time, and does not have other toxic and side effects; the defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome.

The present invention provides a sunscreen composition comprising: (i) TiO2, (ii) ZnO, (iii) triacontanyl PVP, and (iv) VP / hexadecene copolymer, wherein the composition is an oil-in-water emulsion substantially free of low molecular weight, organic UV absorbers, the ratio of (iii):(iv) is less than one, and the composition provides an in vitro SPF as measured by the IN VITRO SPF TEST METHOD of at least 25. The composition is surprisingly low viscosity and provides a high SPF.

The application provides a use of a banana tissue endogenous hormone zeatin in resisting banana wilt, and belongs to the technical field of plant protection. The banana tissue endogenous hormone is zeatin, and experiments prove that in vitro tests (tissue culture bottles and greenhouses) of the zeatin or lutein show that the zeatin can effectively inhibit the growth of TR4 mycelium, exhibits good anti-banana wilt fungus activity, has a significant prevention and control effect on the banana wilt fungus (TR4), and does not affect the growth of seedlings. The application provides a new idea and method for preventing and controlling TR4, and lays a foundation for in-depth exploration of the prevention and control of the banana wilt disease TR4.

The present invention provides in vitro test kits, assays and methods useful for screening for the presence of a ligand in a test sample, the ligand being characterized by its ability, when in a cell, to form a complex with a steroid hormone receptor and cause a genomic response. Advantageously, the activity-based assays that form the basis of the test kits and methods described herein are particularly suitable for detecting the presence of ligands of unknown structure, such as designer drugs used by equine, canine and human athletes in sports doping. Different assay prototypes are disclosed, in which, for example, through the activation of a reporter, hormone receptor activation caused by ligand binding interactions can be detected. In certain instances, the present invention provides test kits, assays and methods involving aptamer:fluorophore reporter constructs for detecting ligands in samples (e.g., collected from athletes at the side of a race track).

The invention provides a harmful outcome path-based chemical reproductive toxicity transfer learning model prediction method, which comprises the following steps of: collecting test data of male and female reproductive toxicity of chemicals in different levels in a harmful outcome path, and preprocessing the test data; randomly splitting the preprocessed test data into a training set, a verification set and a test set, training a source model by using a deep neural network, and obtaining a target model after migration; evaluating the prediction performance of the target model by taking the area under the curve, the F1 score and the balance accuracy as indexes; representing an application domain of the target model according to the index similarity density and the weighted rugged property; and predicting whether the chemicals in the application domain have reproductive toxicity to the living body or not by using the target model. The transfer learning model fully fuses multi-level in-vitro test toxicity data of chemicals from molecular initial events to harmful outcomes, and can accurately predict in-vivo reproductive toxicity.